期刊
DRUG DEVELOPMENT RESEARCH
卷 76, 期 8, 页码 419-427出版社
WILEY
DOI: 10.1002/ddr.21285
关键词
immune-mediated inflammatory diseases; psoriasis; rheumatoid arthritis; inflammatory bowel disease; safety; infection; malignancy; anti-TNFa therapies
资金
- AbbVie
- MSD
- Ferring
- OM Pharma
- Amgen
- Novartis
- Boeringher
- Menarini
- Glaxo-Smith-Klein
- Boehringer Ingelheim
- Janssen
- Leo-Pharma
- Pfizer
The efficacy of anti-TNF agents in the treatment of multiple immune-mediated inflammatory diseases (IMIDs) has increased their daily use. However, concerns remain regarding their long-term safety profile. Using a literature-based review of the infectious and malignant complications of anti-TNF biologics in IMIDs including psoriasis, Rheumatoid Arthritis, and inflammatory bowel disease, this review presents current evidence relative to the safety of anti-TNF agents in the context infections and malignancy in adults with IMIDs. Treatment with anti-TNF biologics is an effective treatment option with known risks that can be mitigated by appreciating the safety aspects and via a thorough screening and continuous monitoring of the patient. (C) 2015 Wiley Periodicals, Inc.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据